



IBA presents the most optimized (c)GMP compliant PET radiopharmacy

IBA experts have been able to design the world's most optimized PET center (96 m² - 1033 ft²) while integrating the new IBA cyclotron

Louvain-la-Neuve, Belgium, May 13th, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy and radiopharmacy solutions, today presents the market's most optimized (c)GMP compliant radiopharmacy, *IntegraLab[®] ONE*. This PET center has a 96 square meter (1033 square feet) foot print and allows a very high production of ¹⁸F for FDG and ⁶⁸Ga.

IntegraLab[®] ONE is the real ready-to-run integrated radiopharmacy. It has been designed to ensure a fast, smooth and risk-free set up of your (c)GMP radiopharmacy. The integrated solution includes all the laboratory equipment and servicing needed to build your radiopharmacy in the best conditions as well as qualification, validation, staff training and maintenance.

This compact design has been made possible due to three different elements: the expertise of IBA facility designers; IBA's new smaller footprint cyclotron (which will be launched at SNNMI annual meeting), and; the exclusive supply of various compact laboratory equipment and the Synthera[®] synthesizer, the most compact in the market.

"IntegraLab[®] ONE is the most optimized PET center of the market and will deliver outstanding performance" said Bruno Scutnaire, President of IBA RadioPharma Solutions, "establishment costs will be drastically reduced and IntegraLab[®] ONE will be qualified in minimum time thanks to the optimal integration of IBA's equipment and those of our world-leading partners. IntegraLab[®] ONE reduces your project time, increases your production uptime and increases your return on investment."

IBA RadioPharma Solutions will be showcasing the *IntegraLab[®] ONE* solution and its new cyclotron during the whole SNMMI congress (San Diego, June 11-14) at booth #1721. More info about IBA's new cyclotron on www.cycloneoftechnology.com

About IBA RadioPharma Solutions

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the start-up of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

About Synthera[®]

Synthera[®] is a multi-purpose automated platform synthesizer for the production of ¹⁸F-FDG and other ¹⁸F-labeled radiopharmaceuticals (¹⁸FCH, ¹⁸FLT, Na¹⁸F, Fdopa,...) and is the smallest available module on the market.



About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The company's expertise lies in the development of next-generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully-integrated IntegraLab® system.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors and provides high quality services and products for oncology specialists and cancer patients.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Rebecca Lo bue

Marketing director

Tel : +32 10 20 12 75

info-cyclo@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com